Amy Beth Vanduyn Sells 1,311 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 1,311 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $34,885.71. Following the completion of the sale, the senior vice president now directly owns 115,633 shares in the company, valued at approximately $3,076,994.13. The trade was a 1.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Amy Beth Vanduyn also recently made the following trade(s):

• On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The stock was sold at an average price of $20.93, for a total transaction of $532,605.71.

Phreesia Stock Performance

Shares of PHR stock opened at $26.75 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.77 and a current ratio of 1.74. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16. The company has a market capitalization of $1.55 billion, a P/E ratio of -18.20 and a beta of 0.94. The stock has a 50 day moving average price of $22.87 and a two-hundred day moving average price of $22.62.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.58) EPS. Analysts expect that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on PHR. Truist Financial boosted their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. KeyCorp upped their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday. JMP Securities restated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Citigroup upped their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday. Finally, Robert W. Baird decreased their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $31.00.

Institutional Trading of Phreesia

A number of institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC raised its position in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares during the last quarter. Lombard Odier Asset Management USA Corp purchased a new position in shares of Phreesia during the second quarter valued at approximately $202,000. Point72 DIFC Ltd bought a new position in shares of Phreesia during the second quarter valued at approximately $209,000. XTX Topco Ltd purchased a new stake in Phreesia in the third quarter worth $247,000. Finally, Hsbc Holdings PLC bought a new stake in Phreesia in the second quarter valued at $301,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.